Market Overview

BioLineRx Presents Positive Preclinical Results of AML Treatment at ASH

Share:

BioLineRx (NASDAQ: BLRX) announced today that positive preclinical results of BL-8040 (formerly known as BKT-140), for the treatment of Acute Myeloid Leukemia (AML) and other hematological indications, have been presented as a poster at the 55th Annual Meeting of the American Society of Hematology (ASH). The data show that BL-8040 is efficient in inducing the death of AML cancer cells both in vitro and in a humanized mouse model. #ASH13

See full press release

Posted-In: News Guidance Management Global

 

Related Articles (BLRX)

View Comments and Join the Discussion!